Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks01-04

Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year. The upside has been primarily driven by the positive regulatory updates regarding ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500263831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-04 02:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500263831","market":"us","top_or_hot":-1,"title":"Here's Why Arcutis Stock More Than Doubled in Market Value in One Year","media":"Zacks","content":"<div>\n<p>Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.\nThe upside has been primarily driven by the positive regulatory updates regarding ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-arcutis-stock-more-182800155.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Arcutis Stock More Than Doubled in Market Value in One Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Arcutis Stock More Than Doubled in Market Value in One Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-04 02:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-arcutis-stock-more-182800155.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.\nThe upside has been primarily driven by the positive regulatory updates regarding ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-arcutis-stock-more-182800155.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-arcutis-stock-more-182800155.html","article_id":"2500263831","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500263831","pubTimestamp":1735928880,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.The upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.This drug is currently approved for use in different formulations – as foam and cream – across different indications.In the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall.In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.SPRO’s earnings beat estimates in two of the trailing four quarters and missed the m","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"这就是Arcutis股票市值一年内上涨一倍多的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1,"CSTL":1,"CTMX":1,"SPRO":0.9},"content_text":"Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.\nThe upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.\nThis drug is currently approved for use in different formulations – as foam and cream – across different indications.\nARQT Stock Performance\nIn the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall.\nImage Source: Zacks Investment Research\nZoryve – A Key Top-Line Driver for Arcutis\nSince its launch, Zoryve has witnessed a strong uptake fueled by the continued growth of unit demand. In the first nine months of 2024, Arcutis recorded product revenues of $97 million, up more than 500% from the year-ago quarter figure. This has also likely contributed to the stock price soaring.\nA 0.3% formulation of Zoryve cream is approved for treating plaque psoriasis in patients six years and older and for seborrheic dermatitis in patients nine years and above. In July, the FDA approved a 0.15% formulation of the cream to treat mild to moderate atopic dermatitis (AD) in adult and pediatric patients six years and older.\nA 0.15% formulation of Zoryve foam is approved to treat seborrheic dermatitis in individuals aged nine years and older.\nLast month, Arcutis submitted an sNDA to the FDA for Zoryve cream 0.05% to treat mild to moderate AD in children two to five years old. An sNDA is already under the agency’s review seeking approval for Zoryve foam 0.3% to treat scalp and body psoriasis, with a final decision expected in May 2025. Potential approvals for these indications will further boost revenues in 2025.\nARQT’s Zacks Rank\nArcutis currently carries a Zacks Rank #3 (Hold).\n\nArcutis Biotherapeutics, Inc. Price\n\nArcutis Biotherapeutics, Inc. price | Arcutis Biotherapeutics, Inc. Quote\n\nKey Picks Among Biotech Stocks\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, Spero Therapeutics SPRO and CytomX Therapeutics CTMX. While CSTL and SPRO sport a Zacks Rank #1 (Strong Buy) at present, CTMX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nBottom-line estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past year, shares of Castle Biosciences have surged 34.9%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 34.9% in the past year.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nArcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500263831"}